OncLive TV

Dr. Karen Reckamp from the City of Hope Cancer Center Discusses the Use of Hsp90 Inhibitors

Dr. Debu Tripathy from USC Norris Cancer Center on Determining the Best HER2 Targeted Therapy

Dr. Matthew Ellis from Washington University Discusses the Cell-Proliferation Marker Ki67

Dr. Ken Yoneda from UC Davis Cancer Center Discusses Bronchoscopy Tools and Procedures

Dr. Joyce O'Shaughnessy from Baylor Sammons Cancer Center on Negative TNBC Iniparib Trial Results

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Dr. Debu Tripathy from UC Norris Cancer Center Discusses HER2 Targeted Therapies

Dr. Ken Yoneda from UC Davis Cancer Center Discusses the Role of the Pulmonologist

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

Dr. Mary J. C. Hendrix from Northwestern University's Feinberg School of Medicine on Metastatic Tumor Cells in Microenvironments

Dr. Debu Tripathy from USC Norris Cancer Center on Completing New Assays After Recurrence

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Avastin as Her Standard of Care

Dr. Karen Reckamp from City of Hope Cancer center Discusses Heat Shock Proteins in Lung Cancer

Dr. Debu Tripathy from USC Norris Cancer Center Describes the Benefits of the PER Conferences

Dr. Antonio C. Wolff from Sidney Kimmel Comprehensive Cancer Center Discusses the Importance of HER2 Testing

Dr. Debu Tripathy from USC Norris Cancer Center on the Oncotype DX Assay Recurrence Score

Dr. Joyce A. O'Shaughnessy from Baylor Sammons Cancer Center on Continued Access to Avastin

Dr. Debu Tripathy from USC Norris Cancer Center Discusses Breast Cancer Gene Profiling

Dr. Debu Tripathy from the USC Norris Comphrensive Cancer Center Discusses Breast Cancer Biomarkers

Dr. Roy S. Herbst from Yale Comprehensive Cancer Center on Themes From the 2011 Lung Cancer Congress

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Available Targeted Therapies

Dr. Roy S. Herbst from Yale comprehensive cancer center on the International Lung Cancer Congress

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses the Next Steps for Ipilimumab

Dr. Roy Herbst from the Yale Comprehensive Cancer Center on Screening Studies at the Upcoming Lung Cancer Congress

Dr. Jack West from the Swedish Cancer Institute Talks About the Escalating Cost of Cancer Care

Dr. Axel Hoos medical lead at Bristol-Myers Squibb Discusses Which Patients are Eligible to Receive Ipilimumab

Dr. Allen S. Lichter the chief executive officer of ASCO on the Importance of the UN Summit on NCD

Dr. Mark G. Kris from Memorial Sloan-Kettering Cancer Center Discusses Patient Acceptance of Mutation Testing

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

Dr. Sandhya Pruthi from the Mayo Clinic in Minnesota on What She Learned From the Flaxseed Trial